287 related articles for article (PubMed ID: 12360485)
21. Mechanism of ursodeoxycholic acid- and canrenoate-induced biliary bicarbonate secretion and the effect on glucose- and amino acid-induced cholestasis.
Omland E; Mathisen O
Scand J Gastroenterol; 1991 May; 26(5):513-22. PubMed ID: 1871544
[TBL] [Abstract][Full Text] [Related]
22. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate.
Rudolph G; Kloeters-Plachky P; Sauer P; Stiehl A
Eur J Clin Invest; 2002 Aug; 32(8):575-80. PubMed ID: 12190957
[TBL] [Abstract][Full Text] [Related]
23. The effects of ursodeoxycholic acid on serum and biliary noncholesterol sterols in patients with gallstones.
Miettinen TE; Tarpila S; Gylling H
Hepatology; 1997 Mar; 25(3):514-8. PubMed ID: 9049189
[TBL] [Abstract][Full Text] [Related]
24. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Holtmeier J; Leuschner U
Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of hepatoprotective action of bile salts in liver disease.
Stiehl A; Benz C; Sauer P
Gastroenterol Clin North Am; 1999 Mar; 28(1):195-209, viii. PubMed ID: 10198785
[TBL] [Abstract][Full Text] [Related]
26. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.
Stiehl A; Rudolph G; Klöters-Plachky P; Sauer P; Walker S
J Hepatol; 2002 Feb; 36(2):151-6. PubMed ID: 11830325
[TBL] [Abstract][Full Text] [Related]
27. Effects of ursodeoxycholic acid on synthesis of cholesterol and bile acids in healthy subjects.
Sauter GH; Thiessen K; Parhofer KG; Jüngst C; Fischer S; Jüngst D
Digestion; 2004; 70(2):79-83. PubMed ID: 15375335
[TBL] [Abstract][Full Text] [Related]
28. Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans.
Lanzarotto F; Panarotto B; Sorbara R; Panteghini M; Pagani F; Sosta S; Lanzini A
Gut; 1999 Apr; 44(4):552-6. PubMed ID: 10075964
[TBL] [Abstract][Full Text] [Related]
29. Effect of oral ursodeoxycholic acid on bile acids tolerance tests in healthy dogs.
Abraham LA; Charles JA; Holloway SA
Aust Vet J; 2004 Mar; 82(3):157-60. PubMed ID: 15088982
[TBL] [Abstract][Full Text] [Related]
30. The mechanism of biliary lipid secretion and its defects.
Elferink RP; Groen AK
Gastroenterol Clin North Am; 1999 Mar; 28(1):59-74, vi. PubMed ID: 10198778
[TBL] [Abstract][Full Text] [Related]
31. Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP [correction of CXP] and preservation of BSEP activities.
Paolini M; Pozzetti L; Montagnani M; Potenza G; Sabatini L; Antelli A; Cantelli-Forti G; Roda A
Hepatology; 2002 Aug; 36(2):305-14. PubMed ID: 12143038
[TBL] [Abstract][Full Text] [Related]
32. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
[TBL] [Abstract][Full Text] [Related]
33. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
34. Effects of ursodeoxycholic acid on hemodynamic and renal function abnormalities induced by obstructive jaundice in rats.
Poo JL; Estanes A; Pedraza-Chaverrí J; Cruz C; Uribe M
Ren Fail; 1995 Jan; 17(1):13-20. PubMed ID: 7770639
[TBL] [Abstract][Full Text] [Related]
35. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of mdr2 gene by peroxisome proliferators in the mouse liver.
Miranda S; Vollrath V; Wielandt AM; Loyola G; Bronfman M; Chianale J
J Hepatol; 1997 Jun; 26(6):1331-9. PubMed ID: 9210621
[TBL] [Abstract][Full Text] [Related]
37. Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid.
Loddenkemper C; Keller S; Hanski ML; Cao M; Jahreis G; Stein H; Zeitz M; Hanski C
Int J Cancer; 2006 Jun; 118(11):2750-7. PubMed ID: 16385573
[TBL] [Abstract][Full Text] [Related]
38. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
Linares Rodríguez A
Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
[No Abstract] [Full Text] [Related]
39. Down-regulation of intestinal scavenger receptor class B, type I (SR-BI) expression in rodents under conditions of deficient bile delivery to the intestine.
Voshol PJ; Schwarz M; Rigotti A; Krieger M; Groen AK; Kuipers F
Biochem J; 2001 Jun; 356(Pt 2):317-25. PubMed ID: 11368757
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of multidrug resistance (mdr) and canalicular multispecific organic anion transporter (cMOAT) genes following extrahepatic biliary obstruction in rats.
Kagawa T; Watanabe N; Sato M; Nakano A; Nishizaki Y; Hosoi K; Takashimizu S; Uchiyama J; Kimura M; Matsuzaki S
Biochem Mol Biol Int; 1998 Mar; 44(3):443-52. PubMed ID: 9556204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
